Dr. Prasun Mishra has been an investor, co-founder, advisor, and board member of several U.S.-based corporations. He has numerous publications in peer-reviewed medical journals and several patents. He has helped develop several drugs and combinations in trials and approved, including belvarafenib, cobimetinib (FDA approved), & Aplidin (an anticancer drug now approved in Australia in combination with dexamethasone)/ Plitidepsin also has antiviral activity and is in Phase 3 trials in COVID 19 patients. He is a co-founder of Precision BioPharma Inc., an antiviral drug development company, and Agility Pharmaceuticals, a technology- driven pharmaceutical company committed to revolutionizing drug discovery & development.
Among his professional associations, he serves American Association for Precision Medicine (AAPM) as the founding president and chair of WISE: World Investors and Entrepreneurs Society, an investment collective with a global investment footprint. He is also a Partner in the Global Health Impact Network. He also served as a founding investor/ advisor to Barcelona Ventures, is a part of a few angel groups, and serves as an advisor to a few venture capital and private equity firms. He also currently serves as a member of the Board of Directors at the University of California San Francisco (UCSF) Health Hub and is an advisor to UCSF’s Catalyst Program, Innovation Ventures, and InVent Fund.
Prior to that, he served as a Scientist & Principal Investigator at the pharma giant Genentech, Roche, where he led one of the world’s most advanced high throughput screening robotics labs and contributed to several drug discovery projects. While at Genentech, he contributed to acquiring a clinical-stage RAF inhibitor. He also was a part of the team that managed and further developed the portfolio of the Roche-Intermmune acquisition.
Before Roche, he was a Principal Investigator at the National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services, US Government, where he was a candidate for the Trans-NIH Earl Stadtman Investigator Tenure Track position. He was also a recipient of two NCI Director’s Innovations Awards. Dr. Mishra received his post-doctoral training at the NIH in Cancer Biology and Genetics.
He received his Ph.D. degree in Cellular and Molecular Pharmacology from Rutgers University with higher honors (Dean’s Research Award and Outstanding Thesis Research Award). Taken together, his research work has been recognized globally with over 40 prestigious awards and over 30 keynote talks & invited lectureships.
Dr. Mishra, a serial entrepreneur, has served as an advisor to several venture capital funds. He is a mentor to startup accelerators, including Indie-Bio, California Life Sciences, JLabs / Johnson & Johnson Innovation, HIMSSS Health 2.0 Zygote accelerator, and Med Labs. Notably, Dr. Mishra is also a founding partner in the Silicon Valley-based M7-Accelerator. Due to his unique perspective and selfless service, he is a highly respected and sought-after mentor to many.